AATD

(redirected from Alpha-1 antitrypsin deficiency)
Also found in: Medical.
AcronymDefinition
AATDAlpha-1 Antitrypsin Deficiency
AATDAviation Applied Technology Directorate
AATDAdvanced Aviation Training Device
AATDArmy Advanced Technology Demonstration
AATDAdapted Alternating Treatments Design
AATDAutomated Articulation Testing Device
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Beyond CF, Vertex has a robust pipeline of investigational medicines in other serious diseases where it has deep insight into causal human biology, such as sickle cell disease, beta thalassemia, pain, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and APOL1-mediated kidney diseases.
Global Alpha-1 Antitrypsin Deficiency Treatment Market, by Route of Administration
Abbreviations COPD: Chronic obstructive pulmonary disease AAT: Alpha-1 antitrypsin AATD: Alpha-1 antitrypsin deficiency ACT study: Alpha-1 coded testing study NGS: Next generation sequencing.
O'Neill, "Alpha-1 antitrypsin deficiency," Respiratory Medicine, vol.
Incalzi, "Alpha-1 antitrypsin deficiency: current perspective from genetics to diagnosis and therapeutic approaches," Current medicinal chemistry, vol.
Alpha-1 antitrypsin deficiency is a common genetic cause of both liver and lung disease affecting an estimated 3.4 million people worldwide.
Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment.
The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, as well as biosurgery products and vaccines.
Baxter's biopharmaceuticals business, with 2013 annual revenues of approximately $6 billion, consists of a diverse portfolio of recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders, and plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions.
Alpha-1 antitrypsin deficiency is a recently identified genetic disease that occurs almost as frequently as cystic fibrosis.
She was treated for Alpha-1 Antitrypsin Deficiency at Birmingham Children's Hospital after research there was boosted by funding from Action Medical Research.
DENVER - Screening for alpha-1 antitrypsin deficiency has benefits in appropriately selected patients with lung disease and their family members, according to Dr.
Full browser ?